Novartis
Novartis begins ‘next-generation’ malaria treatment trial
August 21, 2017Research and Development, Sales and Marketing MMV, Novartis, biotech, drugs, malaria, pharma, pharmaceutical
Novartis, alongside Medicines for Malaria Venture (MMV), have revealed that trials into a new antimalarial compound have begun in a …
Moderna appoint Novartis vet to scale-up manufacturing
August 7, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Moderna, Novartis, biotech, drugs, pharma, pharmaceutical
Moderna Therapeutics, a clinical stage biotechnology company, has appointed Juan Andres to the position of Senior Vice President of Late …
Novartis CEO reasserts 2018 growth expectations, discusses Alcon and Sandoz future
July 18, 2017Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, biosimilars, biotech, healthcare, joe jimenez, leukaemia, pharma, pharmaceuticals
Novartis has reiterated its expectation of sales growth beginning in 2018, as well as a positive outlook for its Alcon …
20 million mosquitoes to be released to limit population
July 17, 2017Research and Development, Sales and Marketing Novartis, Verily, biotech, drugs, google, pharma, pharmaceutical
Releasing 20 million mosquitoes does not sound like the right way to go about reducing the overall population; however, the …
Novartis’ breakthrough cancer treatment receives FDA advisory approval
July 13, 2017Research and Development, Sales and Marketing CAR-T, FDA, Novartis, biotech, drugs, pharma, pharmaceutical
In what could well be a game-changing decision for cancer treatment, the FDA advisory panel gave Novartis’ CAR-T Therapy, CTL019 …
Oxford BioMedica in $100 million manufacturing deal with Novartis
July 6, 2017Manufacturing and Production, Sales and Marketing Novartis, Oxford BioMedica
Oxford BioMedica has announced that it has signed a contract with Novartis to supply the company with materials in a …
Heart failure market to quadruple in ten years to $16 billion
July 6, 2017Sales and Marketing GlobalData, Novartis, heart failure
New research from intelligence firm GlobalData has indicated that the market for heart failure drugs is forecast to expand by …
Novartis gains first-line approval for Zykadia in lung cancer
June 29, 2017Research and Development EMA, European Commission, NSCLC, Novartis
The European Commission has followed the EMA’s CHMP positive opinion by approving Novartis’ Zykadia for first-line treatment of patients with …
UK launch of two Novartis biosimilars could cut NHS costs
June 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Erelzi, Novartis, Rixathon, Sandoz, biosimilar, etanercept, rituximab
Sandoz, a division of Swiss pharma giant Novartis, has revealed that two of its biosimilars – Rixathon (biosimilar rituximab) and …
Novartis lung cancer combo receives FDA approval
June 23, 2017Medical Communications, Sales and Marketing NSCLC, Novartis
Novartis has revealed that its drug Tafinlar (dabrafenib) has received approval from the FDA for use in combination with Mekinist …
Novartis pulls off surprise success in cardiovascular risk
June 22, 2017Research and Development, Sales and Marketing Novartis
Novartis has posted positive news from the Cantos clinical trial study that saw its drug, Canakinumab, pull of a surprise …
Novartis receives positive news in eye drug P3 studies
June 20, 2017Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron
Novartis has achieved positive feedback from its two Phase 3 studies into its eye drug RTH258 (brolucizumab), which found it …
Severe asthma patients require more support, Novartis study suggests
June 19, 2017Research and Development, Sales and Marketing Novartis, asthma
A new study from Novartis has indicated that patients suffering from severe asthma still do not get adequate support to …
Novartis receives European biosimilar approval for Roche blockbuster
June 19, 2017Sales and Marketing Novartis, Rituxan, Rixathon, Roche
Sandoz, a division within Novartis, has received European Commission approval for its biosimilar version of Roche’s Rituxan (also known as …
Novartis’ Cosentyx shines in ankylosing spondylitis and psoriatic arthritis
June 15, 2017Research and Development Cosentyx, Novartis
Novartis has released new data on the efficacy of its drug Cosentyx (secukinumab) in the treatment of life-long inflammatory diseases …
Latest content
FibroFind appoints Lee Borthwick as CEO
